- Open Access
Patients with emm1/T1 serotype invasive group A streptococci infections demonstrated more renal failure than patients with other serotypes: perhaps we should consider some confounders
Critical Care volume 24, Article number: 473 (2020)
We read with great interest the article by Björck et al. who concluded that in their study of critically ill patients with invasive group A streptococcal (iGAS) infections, emm1/T1 was the most dominant serotype and that patients with that serotype demonstrated more circulatory and renal failure than patients with other serotypes of iGAS . We would like to make some comments. Intravenous immunoglobulins (IVIGs) are often used as a part of the treatment of iGAS . We noted that 52% of the emm1/T1 serotype patients received IVIGs as compared to 28% of the patients with other serotypes . The incidence of acute kidney injury (AKI) with IVIGs stabilized with glucose, maltose, d-sorbitol, mannitol, glycine, or l-proline has been found to be lower than that with sucrose-stabilized products . AKI induced by sucrose-containing IVIGs is likely related to the toxic action of sucrose on the nephron, whereby excess sucrose in the kidney causes osmotic nephrosis [2, 3]. Whilst osmotic nephrosis has been reported with sucrose-free IVIGs, the incidence is much lower because the levels of these agents can be closely regulated by enzymes within the kidney [2, 4]. Similarly to sucrose, excessive glucose accumulation can have deleterious effects on the proximal tubules  and, since intravenous glucose infusion is known to produce a rapid increase in blood glucose and insulin levels in normal subjects, diabetic patients are at particular risk of AKI following administration of glucose-stabilized IVIGs . The incidence of diabetes mellitus is not reported in the paper of Björck et al. . It is possible that the increase of AKI in the emm1/T1 serotype group was due to IVIGs. It would be very interesting to know if the IVIGs given to patients in this study were sucrose-stabilized.
Availability of data and materials
Invasive group A streptococci
Acute kidney injury
Björck V, Påhlman LI, Bodelsson M, et al. Morbidity and mortality in critically ill patients with invasive group A streptococcus infection: an observational study. Crit Care. 2020;24:302. https://doi.org/10.1186/s13054-020-03008-z.
Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol. 2013;38(4):275–84. https://doi.org/10.1159/000354893.
Lin RY, Rodriguez-Baez G, Bhargave GA, Lin H. Intravenous gammaglobulin-associated renal impairment reported to the FDA: 2004–2009. Clin Nephrol. 2011;76:365–72.
Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney – a two-edged sword. Semin Arthritis Rheum. 2004;34:593–601.
Ochs HD, Siegel J. Stabilizers used in intravenous immunoglobulin products: a comparative review. Pharm Pract News, 2010.
We would like to thank Dr. Melissa Jackson for the critical review of the manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare to have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Honore, P.M., Barreto Gutierrez, L., Kugener, L. et al. Patients with emm1/T1 serotype invasive group A streptococci infections demonstrated more renal failure than patients with other serotypes: perhaps we should consider some confounders. Crit Care 24, 473 (2020). https://doi.org/10.1186/s13054-020-03180-2